Article and Video CATEGORIES

Cancer Journey

Search By

Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
Author
GRACE Videos and Articles
Image

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

Get more information about the FLAURA Trial and TIGER-1 Trial.

 

Next Previous link

Previous PostNext Post

Related Content

Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora
Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 

Forum Discussions

I don't know what to do. No insurance

Hi Ascardino, Welcome to Grace. I'm so sorry to hear of your situation.  While we don't have specific info or expertise on ovarian cancer, I did some searching for information.  It...

Recent Comments

JOIN THE CONVERSATION
Hi Ascardino, Welcome to…
By JanineT GRACE … on
I don't know what to do. No…
By Ascardino on
Hi Hopish hope,  Welcome to…
By JanineT GRACE … on